$0.11
0.00%
Nasdaq, Sep 05, 03:30 pm CET
ISIN
NL0014040206
Symbol
CNTG

Centogene NV Stock price

$0.11
-0.24 69.16% 1M
-0.56 84.04% 6M
-1.09 91.09% YTD
-0.98 90.19% 1Y
-10.43 98.99% 3Y
-12.38 99.14% 5Y
-12.38 99.14% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.00 0.09%
ISIN
NL0014040206
Symbol
CNTG
Sector
Industry

Key metrics

Market capitalization $3.10m
Enterprise Value $70.75m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.35
P/S ratio (TTM) P/S ratio 0.06
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $52.47m
EBIT (operating result TTM) EBIT $-44.41m
Free Cash Flow (TTM) Free Cash Flow $-40.86m
EPS (TTM) EPS $-1.37
P/E forward negative
P/S forward 0.21
EV/Sales forward 0.98
Short interest 0.70%
Show more

Is Centogene NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Centogene NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Centogene NV:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Centogene NV:

Buy
100%

Financial data from Centogene NV

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
52 52
-
100%
- Direct Costs 34 34
-
64%
19 19
-
36%
- Selling and Administrative Expenses 41 41
-
79%
- Research and Development Expense 13 13
-
25%
-36 -36
-
-69%
- Depreciation and Amortization 8.23 8.23
-
16%
EBIT (Operating Income) EBIT -44 -44
-
-85%
Net Profit -38 -38
-
-73%

In millions USD.

Don't miss a Thing! We will send you all news about Centogene NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Centogene NV Stock News

Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE'S common stock from Nasdaq. The not...
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data from the Company's Rostock International Parkinson's Disease (ROPAD) Study revealing the genetic factors and prevalence of Parkinson's disease (PD). The findings ...
Neutral
GlobeNewsWire
3 months ago
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a Memorandum of Und...
More Centogene NV News

Company Profile

Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.

Head office Netherlands
CEO Kim Stratton
Employees 493
Founded 2018
Website www.centogene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today